304 related articles for article (PubMed ID: 33818748)
1. The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder.
De Aquino JP; Parida S; Sofuoglu M
Clin Drug Investig; 2021 May; 41(5):425-436. PubMed ID: 33818748
[TBL] [Abstract][Full Text] [Related]
2. Buprenorphine Microdosing Cross Tapers: A Time for Change.
Raheemullah A; Benhamou OM; Kuo J; Lembke A
Int J Environ Res Public Health; 2022 Dec; 19(24):. PubMed ID: 36554317
[TBL] [Abstract][Full Text] [Related]
3. Management of opioid withdrawal and initiation of medications for opioid use disorder in the hospital setting.
Carswell N; Angermaier G; Castaneda C; Delgado F
Hosp Pract (1995); 2022 Oct; 50(4):251-258. PubMed ID: 35837678
[TBL] [Abstract][Full Text] [Related]
4. Successful Buprenorphine/Naloxone Low-dose Induction in Pregnancy: A Case Report.
Coish R; Hardial J
J Addict Med; 2023 Jan-Feb 01; 17(1):114-116. PubMed ID: 35916416
[TBL] [Abstract][Full Text] [Related]
5. Adjunctive memantine for opioid use disorder treatment: A systematic review.
Elias AM; Pepin MJ; Brown JN
J Subst Abuse Treat; 2019 Dec; 107():38-43. PubMed ID: 31757263
[TBL] [Abstract][Full Text] [Related]
6. Synergistic Effect of Ketamine and Buprenorphine Observed in the Treatment of Buprenorphine Precipitated Opioid Withdrawal in a Patient With Fentanyl Use.
Hailozian C; Luftig J; Liang A; Outhay M; Ullal M; Anderson ES; Kalmin M; Shoptaw S; Greenwald MK; Herring AA
J Addict Med; 2022 Jul-Aug 01; 16(4):483-487. PubMed ID: 34789683
[TBL] [Abstract][Full Text] [Related]
7. Buprenorphine Microdose Induction for the Management of Prescription Opioid Dependence.
Robbins JL; Englander H; Gregg J
J Am Board Fam Med; 2021 Feb; 34(Suppl):S141-S146. PubMed ID: 33622829
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Tramadol Extended-Release for Opioid Withdrawal: A Randomized Clinical Trial.
Dunn KE; Tompkins DA; Bigelow GE; Strain EC
JAMA Psychiatry; 2017 Sep; 74(9):885-893. PubMed ID: 28700791
[TBL] [Abstract][Full Text] [Related]
9. Approach to buprenorphine use for opioid withdrawal treatment in the emergency setting.
Cisewski DH; Santos C; Koyfman A; Long B
Am J Emerg Med; 2019 Jan; 37(1):143-150. PubMed ID: 30355476
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
[TBL] [Abstract][Full Text] [Related]
11. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
[TBL] [Abstract][Full Text] [Related]
12. Assessment of pioglitazone and proinflammatory cytokines during buprenorphine taper in patients with opioid use disorder.
Schroeder JR; Phillips KA; Epstein DH; Jobes ML; Furnari MA; Kennedy AP; Heilig M; Preston KL
Psychopharmacology (Berl); 2018 Oct; 235(10):2957-2966. PubMed ID: 30079432
[TBL] [Abstract][Full Text] [Related]
13. Effects associated with double-blind omission of buprenorphine/naloxone over a 98-h period.
Correia CJ; Walsh SL; Bigelow GE; Strain EC
Psychopharmacology (Berl); 2006 Dec; 189(3):297-306. PubMed ID: 17013637
[TBL] [Abstract][Full Text] [Related]
14. The effectiveness of different singly administered high doses of buprenorphine in reducing suicidal ideation in acutely depressed people with co-morbid opiate dependence: a randomized, double-blind, clinical trial.
Ahmadi J; Jahromi MS; Ehsaei Z
Trials; 2018 Aug; 19(1):462. PubMed ID: 30157924
[TBL] [Abstract][Full Text] [Related]
15. Opioid dependence treatment: options in pharmacotherapy.
Stotts AL; Dodrill CL; Kosten TR
Expert Opin Pharmacother; 2009 Aug; 10(11):1727-40. PubMed ID: 19538000
[TBL] [Abstract][Full Text] [Related]
16. Low-dose overlap initiation with split tablets of buprenorphine in intubated intensive care unit patients with opioid use disorder.
Szczesniak L; Britton S; Rn TB; Sullivan R
Harm Reduct J; 2024 Jun; 21(1):114. PubMed ID: 38849912
[TBL] [Abstract][Full Text] [Related]
17. Managing opioid withdrawal precipitated by buprenorphine with buprenorphine.
Oakley B; Wilson H; Hayes V; Lintzeris N
Drug Alcohol Rev; 2021 May; 40(4):567-571. PubMed ID: 33480051
[TBL] [Abstract][Full Text] [Related]
18. Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report.
Szczesniak LM; Calleo VJ; Sullivan RW
Harm Reduct J; 2020 Oct; 17(1):71. PubMed ID: 33028340
[TBL] [Abstract][Full Text] [Related]
19. Effects of buprenorphine/naloxone in opioid-dependent humans.
Stoller KB; Bigelow GE; Walsh SL; Strain EC
Psychopharmacology (Berl); 2001 Mar; 154(3):230-42. PubMed ID: 11351930
[TBL] [Abstract][Full Text] [Related]
20. Buprenorphine precipitated opioid withdrawal: Prevention and management in the ED setting.
Spadaro A; Long B; Koyfman A; Perrone J
Am J Emerg Med; 2022 Aug; 58():22-26. PubMed ID: 35623179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
